The most recent short interest data was recently released for the 10/15/2018 settlement date, and Novavax, Inc. is one of the most shorted stocks of the Russell 3000, based on 8.21 "days to cover" versus the median component at 4.82.
Investors in Novavax, Inc. saw new options become available this week, for the December 21st expiration.
Investors in Novavax, Inc. saw new options become available this week, for the November 16th expiration.
The most recent short interest data was recently released for the 07/13/2018 settlement date, and Novavax, Inc. is one of the most shorted stocks of the Russell 3000, based on 18.69 "days to cover" versus the median component at 6.06.
Investors in Novavax, Inc. saw new options become available this week, for the October 19th expiration.
Investors in Novavax, Inc. saw new options become available this week, for the March 16th expiration.
In trading on Wednesday, shares of Novavax, Inc. touched a new 52-week high of $1.98/share.
Novel vaccine candidate, NanoFlu™, outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study
Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 7,426,054 share decrease in total short interest for Novavax, Inc. , to 56,851,825, a decrease of 11.55% since 06/15/2017.
Alexion, Arena and Novavax were among the biotech stock movers ahead of the market open on Friday, July 7.
